Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment

Abstract

Our findings suggest that lumacaftor/ivacaftor reduces lung function decline, improves lung function, physical performance, and HRQOL to a greater extent in PWCF with severe lung disease than previously recognized.